Investors reduce holdings in Thermo Fisher and TG Therapeutics

GW&K Investment Management lowered its stake in Thermo Fisher Scientific by 7.9% in the fourth quarter, selling 2,788 shares and ending the period with 32,660 shares valued at roughly $18.9 million. Other institutional investors also adjusted positions in Thermo Fisher, with Portfolio Design Labs raising its stake by 8.0% and Alteri Wealth increasing its holding by 37.8% during the same period.

WINTON GROUP Ltd cut its ownership of TG Therapeutics sharply, decreasing its position by 79.8% in the fourth quarter, selling 99,758 shares and retaining 25,242 shares worth about $752,000. Additional investors such as Vanguard, State Street and Goldman Sachs made modest purchases, increasing their stakes in TG Therapeutics during the quarter.

Both filings reflect routine portfolio rebalancing by large investors in the biotech and medical‑research sectors, with no immediate corporate actions reported beyond the disclosed share transactions.